-
Mashup Score: 0Benefit of concurrent versus sequential chemoradiotherapy in elderly patients with stage III non-small cell lung cancer - 3 year(s) ago
: Lung cancer is the largest cause of cancer-related deaths worldwide. 85% of patients is diagnosed with non-small cell lung cancer. Almost a third of patients is aged over 75, but this group is poorly represented in clinical trials. This study compares the effects of therapy in non-operable stage III NSCLC in elderly patients compared to their younger counterparts.
Source: Clinical Lung CancerCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 0Safety and efficacy of extended interval dosing for immune checkpoint inhibitors in non-small cell lung cancer during the COVID-19 pandemic - 3 year(s) ago
Extended interval (EI) dosing for immune checkpoint inhibitor (ICI) mono- or consolidation therapy initiated due to the COVID-19 pandemic led to a significant reduction in ICI-related site visits for patients with stage III and IV non-small cell lung cancer (NSCLC). Here we report the safety and efficacy compared to standard dose (SD) schedules.
Source: Clinical Lung CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
Safety and efficacy of extended interval dosing for immune checkpoint inhibitors in non-small cell lung cancer during the COVID-19 pandemic #COVID19 #immunotherapy #lcsm https://t.co/cR61BatFHN
-
-
Mashup Score: 0
1Non-small cell lung cancer (NSCLC) is the number one cancer killer in the United States, causing more deaths than colon, breast, and prostate cancer combined.1 The landmark NCI-sponsored National Lung Screening Trial (NLST) randomized control trial screened high-risk, current, and former smokers for 3 years with low dose computed tomography scan (LDCT).2 Studies estimate a reduction of NSCLC…
Source: Clinical Lung CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
Link here https://t.co/bCcZcyJxLq https://t.co/C7a3dX8l2c
-
-
Mashup Score: 2Safety and efficacy of extended interval dosing for immune checkpoint inhibitors in non-small cell lung cancer during the COVID-19 pandemic - 3 year(s) ago
Extended interval (EI) dosing for immune checkpoint inhibitor (ICI) mono- or consolidation therapy initiated due to the COVID-19 pandemic led to a significant reduction in ICI-related site visits for patients with stage III and IV non-small cell lung cancer (NSCLC). Here we report the safety and efficacy compared to standard dose (SD) schedules.
Source: Clinical Lung CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
Retrospective look in #CLC at patients with NSCLC receiving PD(L)1 inhibitors using standard/initial dosing schedules or extended interval dosing showed fairly comparable results. Extended dosing leads to less visits, less #COVID19 exposure risk. #LCSM https://t.co/iVG9Tc45pr
-
-
Mashup Score: 0Benefit of concurrent versus sequential chemoradiotherapy in elderly patients with stage III non-small cell lung cancer - 3 year(s) ago
: Lung cancer is the largest cause of cancer-related deaths worldwide. 85% of patients is diagnosed with non-small cell lung cancer. Almost a third of patients is aged over 75, but this group is poorly represented in clinical trials. This study compares the effects of therapy in non-operable stage III NSCLC in elderly patients compared to their younger counterparts.
Source: Clinical Lung CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
Retrospective analysis of 750pts with stage III NSCLC treated with concurrent or sequential chemo and radiation: OS better in concurrent (HR 0.68), even in elderly. Several confounders and pre-immunotherapy era but supports concurrent in eligible pts. https://t.co/BbMSLi5EFr
-
-
Mashup Score: 0
1Non-small cell lung cancer (NSCLC) is the number one cancer killer in the United States, causing more deaths than colon, breast, and prostate cancer combined.1 The landmark NCI-sponsored National Lung Screening Trial (NLST) randomized control trial screened high-risk, current, and former smokers for 3 years with low dose computed tomography scan (LDCT).2 Studies estimate a reduction of NSCLC…
Source: Clinical Lung CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
Low dose CT lung cancer screening saves lives but referral rates are low. In centers that serve marginalized populations, this widens disparities. An education program focused on providers and medical assistants significantly increased use of screening. https://t.co/MuCCpyb8lo https://t.co/bm6AEuPjiC
-
-
Mashup Score: 2
: Patients with EGFR-mutant lung cancer who have had disease progression on osimertinib commonly receive platinum doublet chemotherapy, but whether adding immunotherapy or bevacizumab provides additional benefit is unknown.
Source: Clinical Lung CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
Retrospective review of post-TKI therapy in #EGFR NSCLC now in #CLC @ELS_Oncology. Pts receiving chemo + immunotherapy did not fare as well as chemo + bevacizumab or chemo alone. Is the bev the key to garnering IO response in EGFR mutant NSCLC? #LCSM https://t.co/qjsd7X4rMb
-
-
Mashup Score: 4Impact of tumor suppressor gene co-mutations on differential response to EGFR TKI therapy in EGFR L858R and exon 19 deletion lung cancer - 4 year(s) ago
In most studies, patients with EGFR L858R mutant non-small cell lung cancer (NSCLC) have a shorter duration of response to EGFR tyrosine kinase inhibitor (TKI) therapy than do patients with EGFR exon 19 deletion NSCLC. The role that co-mutations play in this observation is unknown.
Source: Clinical Lung CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
In most #EGFR NSCLC studies, exon 19 deletion associated with better outcomes than exon 21 L858R. This single center analysis explores co-mutations in tumor suppressor genes between the two. Could KEAP1 alterations be playing a role in EGFR mutant NSCLC? https://t.co/FTMW7hF1uV
-
-
Mashup Score: 2
Lung cancer remains the leading cause of cancer-related mortality.1 With the identification of various driver mutations, the treatment paradigm for the management of advanced NSCLC has shifted from a chemotherapy-based approach to one featuring molecularly targeted therapies. For patients with metastatic NSCLC whose tumor cells are harboring sensitizing mutations in EGFR (exon 19 deletion, exon…
Source: Clinical Lung CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
Report that #HER2 alterations (mutations and amplification) in #EGFR mutant NSCLC are uncommon but potentially important events. Work in #CLC @ELS_Oncology led by Dr. @MNagasaka. #LCSM https://t.co/KLvao5HMz5
-
-
Mashup Score: 1
Micro-AbstractTreatment allocation by epidermal growth factor receptor mutation status is a new standard in patients with metastatic non–small-cell lung cancer. Yet, relatively few modern chemotherapy trials were conducted in patients characterized by epidermal growth factor receptor wild type. We describe the results of a multicenter phase II trial, testing in parallel 2 novel combination…
Source: Clinical Lung CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
@StephenVLiu @myESMO Indeed a very long history of „promising“ trials with VEGF Inhibitors (including our own). Lets focus on new drugs now https://t.co/Cx1LhXoVEQ
-
Patients of all ages with stage III NSCLC benefit from concurrent chemoradiotherapy compared to sequential chemoradiotherapy https://t.co/pn2QSkCJG8